glp 1 asa guidelines The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on Indications for GLP-1/GIP RA Summary

Description

Nat Immunol

Critical Methodological Limitations: The authors note that the vast majority of existing trials carry a high risk of bias, were funded directly by pharmaceutical firms, and rarely enrolled participants holding a formal, standalone clinical diagnosis of BED

Polex-Wolf J, Deibler K, Hogendorf WF, Bau S, Glendorf T, Stidsen CE, et al

Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P: Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

Data presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) 2025, a few months back, have provided new insights into the potential role of metformin within a GLP-1 RA-based regimen continuum, with findings that extend beyond glycaemic outcomes into territory that carries greater clinical weight